-
公开(公告)号:BR9808017A
公开(公告)日:2000-03-08
申请号:BR9808017
申请日:1998-03-05
Applicant: BASF AG
Inventor: RITTER KURT , AMBERG WILHELM , BARLOZZARI TERESA , HAUPT ANDREAS , JANSSEN BERND , KLING ANDREAS
Abstract: The present invention relates to novel peptides useful as anti-cancer agents. The compounds of the invention are of Formula I,A-B-D-E-F-G(I)A, B, D, and E are alpha -amino acid residues. In one embodiment, F is an azacycloalkanecarboxylic acid residue. In this embodiment, G is a monovalent radical, for example, a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group. In another embodiment, F is an azacycloalkyl group and G is a heteroaryl group connected to F by a carbon-carbon bond. In another embodiment, the invention includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
-
公开(公告)号:CZ321199A3
公开(公告)日:2000-02-16
申请号:CZ321199
申请日:1998-03-09
Applicant: BASF AG
Inventor: BARLOZZARI TERESA , HAUPT ANDREAS
IPC: A61K38/00 , A61K31/337 , A61K38/07 , A61K38/08 , A61K38/15 , A61P35/00 , C07K5/08 , C07K5/10 , C07K7/00 , A61K38/04
Abstract: The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of Formula I as defined herein in combination with paclitaxel, taxotere or modified taxane or taxoid analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.
-
公开(公告)号:DE59507578D1
公开(公告)日:2000-02-10
申请号:DE59507578
申请日:1995-04-26
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANITSCHKE LOTHAR , JANSSEN BERND , KARL ULRICH , KLING ANDREAS , MUELLER STEFAN , DE POTZOLLI BERND , RITTER KURT , THYES MARCO , ZIERKE THOMAS
Abstract: PCT No. PCT/EP95/01577 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/30691 PCT Pub. Date Nov. 16, 1995The compound Me2Val-Val-MeVal-Pro-Pro-NHBzlxHCl is described. It is prepared from Z-Val-Val-MeVal-Pro-OR1 where Z and R1 have the meanings stated in the description. The compound shows antineoplastic activity.
-
公开(公告)号:ZA986358B
公开(公告)日:2000-01-17
申请号:ZA986358
申请日:1998-07-17
Applicant: BASF AG
Inventor: JANSSEN BERND , BARLOZZARI TERESA , HAUPT ANDREAS , ZIERKE THOMAS , KLING ANDREAS
Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
-
公开(公告)号:DE59603295D1
公开(公告)日:1999-11-11
申请号:DE59603295
申请日:1996-07-12
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANSSEN BERND , ULRICH KARL , KLING ANDREAS , MUELLER STEFAN , RITTER KURT , ZIERKE THOMAS
IPC: C07K1/02 , C07K1/12 , C07K5/06 , C07K5/078 , C07K5/08 , C07K5/083 , C07K5/10 , C07K5/103 , C07K7/06
Abstract: PCT No. PCT/EP96/03073 Sec. 371 Date Jan. 13, 1998 Sec. 102(e) Date Jan. 13, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97/05162 PCT Pub. Date Feb. 13, 1997A process for preparing pentapeptides of the formula I where A and R1-R3 have the stated meanings, comprises assembling the pentapeptide stepwise starting from a prolinamide of the formula II where R1 and R2 have the abovementioned meanings, and eliminating the group -NR1R2 by hydrolysis where appropriate the peptide obtained in this way.
-
公开(公告)号:BR9609423A
公开(公告)日:1999-06-29
申请号:BR9609423
申请日:1996-06-03
Applicant: BASF AG
Inventor: HAUPT ANDREAS , EMLING FRANZ , ROMERDAHL CYNTHIA A
Abstract: Novel compounds of the formulaR1R2N-CHX-CO-A-B-D-(E)s-(F)t-(G)U-KIin which R1, R2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
-
公开(公告)号:HU9802570A2
公开(公告)日:1999-04-28
申请号:HU9802570
申请日:1996-07-12
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANSSEN BERND , KLING ANDREAS , MUELLER STEFAN , RITTER KURT , ULRICH KARL , ZIERKE THOMAS
IPC: C07K1/02 , C07K1/12 , C07K5/06 , C07K5/078 , C07K5/08 , C07K5/083 , C07K5/10 , C07K5/103 , C07K7/06
Abstract: PCT No. PCT/EP96/03073 Sec. 371 Date Jan. 13, 1998 Sec. 102(e) Date Jan. 13, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97/05162 PCT Pub. Date Feb. 13, 1997A process for preparing pentapeptides of the formula I where A and R1-R3 have the stated meanings, comprises assembling the pentapeptide stepwise starting from a prolinamide of the formula II where R1 and R2 have the abovementioned meanings, and eliminating the group -NR1R2 by hydrolysis where appropriate the peptide obtained in this way.
-
公开(公告)号:AU9502498A
公开(公告)日:1999-04-27
申请号:AU9502498
申请日:1998-09-24
Applicant: BASF AG
Inventor: BARLOZZARI TERESA , BANERJEE SUBHASHIS , HAUPT ANDREAS
Abstract: The present invention provides compositions and methods for the treatment of rheumatoid arthritis in a subject wherein one or more compounds of Formula I as defined herein alone or in combination with one or more other antiarthritic drugs provide suppression of rheumatoid arthritis.
-
公开(公告)号:ZA976723B
公开(公告)日:1999-02-12
申请号:ZA976723
申请日:1997-07-29
Applicant: BASF AG
Inventor: BARLOZZARI TERESA , HAUPT ANDREAS , JANSSEN BERND , GRIESINGER CHRISTIAN , BELIK DANIEL , BORETZKY MICHAEL
Abstract: The present invention provides anti-tumor peptides of Formula I,A-B-NR3-CHD-CH(OCH3)-CH2CO-E-K(I),and the acid salts thereof. A is an amino acid residue selected from the group consisting of N-methyl-D-prolyl, N-methyl-D-homoprolyl and N,N-dimethyl-2-ethylphenylglycyl, or an amino acid residue of the formula R1R2N-CHX-CO, wherein R1 is a-methyl group or an ethyl group, R2 is a hydrogen atom, a methyl group or an ethyl group, and X is an alkyl group. B is an amino acid residue selected from the group consisting of valyl, isoleucyl, leucyl, and 2-t-butylglycyl. R3 is a hydrogen atom or a methyl group. D is a normal or branched C2-C5-alkyl group. E is an amino acid residue selected from the group consisting of prolyl, homoprolyl, 5-methylprolyl, and phenylalanyl, or E is a residue derived from an amino acid comprising a pyrrolidine group. K is an alkoxy group or an amino group. An additional embodiment of the present invention is a method for treating a malignancy in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound or compounds of Formula I in a pharmaceutically acceptable composition.
-
公开(公告)号:AU8475898A
公开(公告)日:1999-02-10
申请号:AU8475898
申请日:1998-07-07
Applicant: BASF AG , BASF BIORESEARCH CORP
Inventor: JANSSEN BERND , BARLOZZARI TERESA , HAUPT ANDREAS , ZIERKE THOMAS , KLING ANDREAS
Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
-
-
-
-
-
-
-
-
-